OMCL or HIMS: Which Is the Better Value Stock Right Now?
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Wall Street Analysts Believe Omnicell ( OMCL ) Could Rally 34.53%: Here's is How to Trade
The consensus price target hints at a 34.5% upside potential for Omnicell (OMCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell ( OMCL Quick QuoteOMCL - ) and Hims & Hers Health, Inc. ( HIMS Quick QuoteHIMS - ) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer ...
Evoke Pharma Rockets On Grabbing 140% Premium In Acquisition Deal - Evoke Pharma ( NASDAQ:EVOK )
Evoke Pharma, Inc. ( NASDAQ:EVOK ) shares are surging on Tuesday after the company announced it has entered into a deal to be acquired by QOL Medical for $11 per share in cash via a tender offer. The purchase price offers a 139.7% premium to Evoke's November 3, 2025, closing share price.
Buy 5 Stocks With Extensive Robotics Application for the Rest of 2025
Five robotics-driven stocks - PATH, EMR, TRMB, OMCL and LECO - are set to gain traction heading into late 2025.
Earnings Estimates Moving Higher for Omnicell ( OMCL ) : Time to Buy?
Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Why Omnicell Stock Crushed the Market Today
The company continues to benefit from demand for its next-generation healthcare tech offerings.
Omnicell ( OMCL ) Q3 Earnings and Revenues Surpass Estimates
Omnicell (OMCL) delivered earnings and revenue surprises of +41.67% and +5.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health, Inc. ( HIMS ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts See a 43.74% Upside in Omnicell ( OMCL ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 43.7% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Earnings Preview: Omnicell ( OMCL ) Q3 Earnings Expected to Decline
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Investors Undervaluing Omnicell ( OMCL ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
10x Genomics ( TXG ) Moves 11.1% Higher: Will This Strength Last?
10x Genomics (TXG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
OMCL or HIMS: Which Is the Better Value Stock Right Now?
OMCL vs. HIMS: Which Stock Is the Better Value Option?
NVDA & PLTR Driving AI in Health: Top Health IT Stocks for Q3 Earnings
NVDA and PLTR drive AI integration across healthcare, fueling optimism for Omnicell and Tempus AI's Q3 performance.
Is Omnicell ( OMCL ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Reasons to Add Omnicell Stock to Your Portfolio Right Now
OMCL's expanding SaaS portfolio, overseas growth plans, and solid balance sheet position it for sustained momentum despite rising competition.
OMCL or HIMS: Which Is the Better Value Stock Right Now?
OMCL vs. HIMS: Which Stock Is the Better Value Option?
BD & Henry Ford Health Tie-Up to Enhance Community Pharmacy Experience
BDX partners with Henry Ford Health to deploy BD Rowa Vmax robots, aiming to streamline 24/7 pharmacy access in Michigan.
OptimizeRx Bets on AI and Workflow Integration - Will This Pay Off?
OPRX posts 55% revenue growth and raises outlook as AI-driven workflow integration fuels leverage and pharma adoption.
Is Omnicell ( OMCL ) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
OMCL or HIMS: Which Is the Better Value Stock Right Now?
OMCL vs. HIMS: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Butterfly Network, Omnicell, NVIDIA, Palantir and IBM
Butterfly Network and Omnicell stand out as top health-tech stocks benefiting from AI, machine learning, and quantum advancements in healthcare, alongside NVIDIA, Palantir, and IBM driving transformative innovations.
NVIDIA, AI & Quantum Leaders Drive Health Tech: 2 Stocks to Buy
Butterfly Network and Omnicell emerge as standout health tech stocks as AI and quantum breakthroughs reshape diagnostics and medication management.
Wall Street Analysts Think Omnicell ( OMCL ) Could Surge 39.36%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 39.4% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Why Is Inspire ( INSP ) Up 7.5% Since Last Earnings Report?
Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Earnings Estimates Rising for Omnicell ( OMCL ) : Will It Gain?
Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts Believe Omnicell ( OMCL ) Could Rally 34.18%: Here's is How to Trade
The consensus price target hints at a 34.2% upside potential for Omnicell (OMCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship - Omnicell ( NASDAQ:OMCL ) , Evoke Pharma ( NASDAQ:EVOK )
Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement Gimoti Specialty Pharmacy Network to Almost Double with Additional Relationships SOLANA BEACH, Calif. and CHICAGO, Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Evoke Pharma, Inc.
Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship
Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement ...
Wall Street Analysts See a 44.47% Upside in Omnicell ( OMCL ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Omnicell (OMCL) points to a 44.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Omnicell ( OMCL ) Beats Q2 Earnings and Revenue Estimates
Omnicell (OMCL) delivered earnings and revenue surprises of +45.16% and +4.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Sustained Product Demand Drive HIMS Stock Before Q2 Earnings?
Hims & Hers benefits from strong product demand and subscriber growth ahead of second-quarter 2025 earnings, fueled by weight loss and specialty care uptake.
OMCL vs. DOCS: Which Stock Is the Better Value Option?
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell ( OMCL Quick QuoteOMCL - ) and Doximity ( DOCS Quick QuoteDOCS - ) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Inspire Medical Systems ( INSP ) Expected to Beat Earnings Estimates: Should You Buy?
Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Omnicell ( OMCL ) to Report a Decline in Earnings: What to Look Out for
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
American Well ( AMWL ) Soars 5.0%: Is Further Upside Left in the Stock?
American Well (AMWL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Can OPRX's Patient Engagement Tools Win Amid Fierce Competition?
OptimizeRx bets on EHR-linked messaging and geo-targeting to stand out, but scaling in a crowded digital health field remains key.
3 Medical Info Systems Stocks to Buy Amid AI Boom and Tariff Risk
AI momentum and rising demand for digital care put Zacks Medical Info Systems industry stocks like VEEV, TXG and IMDX in focus despite new tariff headwinds.
Capsa Healthcare Unveils Industry's First Consolidated Services Pharmacy Platform
CANAL WINCHESTER, Ohio, July 08, 2025 ( GLOBE NEWSWIRE ) -- Capsa Healthcare, a leader in healthcare automation and medication management, today announced the launch of its Consolidated Services Pharmacy Platform ( CSPP ) - the industry's first integrated solution that unifies central fill ...
Do Options Traders Know Something About Omnicell Stock We Don't?
Investors need to pay close attention to OMCL stock based on the movements in the options market lately.
Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
OMCL stays on investors' radar due to its strong 2025 growth targets with automation and tech services, but faces margin risks from macro and competitive headwinds.
Omnicell ( OMCL ) Up 27% Since Last Earnings Report: Can It Continue?
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Advance Auto Parts Posts Upbeat Results, Joins Domo, LiveRamp, Urban Outfitters And Other Big Stocks Moving Higher On Thursday - Advance Auto Parts ( NYSE:AAP ) , Cantor Equity Partners ( NASDAQ:CEP )
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Thursday. Shares of Advance Auto Parts, Inc. AAP rose sharply during Thursday's session following better-than-expected first-quarter financial results.
Omnicell's New Perioperative Clinic Setting Products May Boost Stock
OMCL unveils new offerings for the perioperative and clinic setting.
This PVH Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Ameren ( NYSE:AEE ) , Establishment Labs Hldgs ( NASDAQ:ESTA )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Mike Matson upgraded the rating for Establishment Labs Holdings Inc.
Omnicell Q1 Earnings & Revenues Beat, '25 EPS View Down, Stock Up
OMCL posts better-than-expected top and bottom-line results for the first quarter of 2025.
Omnicell ( OMCL ) Beats Q1 Earnings and Revenue Estimates
Omnicell (OMCL) delivered earnings and revenue surprises of 62.50% and 4.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Sustained Product Demand Drive HIMS Stock Before Q1 Earnings?
The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the first quarter of 2025.
